KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Capital Expenditures (2016 - 2025)

Regeneron Pharmaceuticals (REGN) has 16 years of Capital Expenditures data on record, last reported at $248.7 million in Q4 2025.

  • For Q4 2025, Capital Expenditures rose 161.45% year-over-year to $248.7 million; the TTM value through Dec 2025 reached $315.2 million, up 107.92%, while the annual FY2025 figure was $898.4 million, 492.61% up from the prior year.
  • Capital Expenditures reached $248.7 million in Q4 2025 per REGN's latest filing, up from $229.3 million in the prior quarter.
  • Across five years, Capital Expenditures topped out at $248.7 million in Q4 2025 and bottomed at -$404.7 million in Q4 2024.
  • Average Capital Expenditures over 4 years is $70.5 million, with a median of $133.9 million recorded in 2024.
  • Peak YoY movement for Capital Expenditures: crashed 56.03% in 2021, then soared 161.45% in 2025.
  • A 4-year view of Capital Expenditures shows it stood at $133.2 million in 2021, then tumbled by 344.89% to -$326.2 million in 2022, then fell by 24.06% to -$404.7 million in 2024, then skyrocketed by 161.45% to $248.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Capital Expenditures were $248.7 million in Q4 2025, $229.3 million in Q1 2025, and -$404.7 million in Q4 2024.